Lemon Balm vs Ozempic: Why a Medicinal Herb Can't Replace a GLP-1 Medication (and What the Research Actually Shows)

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Ozempic (semaglutide) is a prescription GLP-1 receptor agonist with FDA approval for type 2 diabetes and proven 15-20% body weight reduction in clinical trials; lemon balm is an herbal supplement with mild anxiolytic and metabolic effects but no FDA approval for any medical condition
• No published clinical trial has directly compared lemon balm to semaglutide, and the mechanisms of action are fundamentally different (receptor-specific hormone mimicry vs broad polyphenol activity)
• Lemon balm shows modest effects on fasting glucose (8-12 mg/dL reductions in small studies) and may reduce stress-related eating, but cannot replicate the appetite suppression, gastric emptying delay, or insulin secretion enhancement of GLP-1 medications
• The two can be used together safely with no known drug interactions, and some patients use lemon balm to manage GLP-1-related anxiety or sleep disruption during titration

Direct answer (40-60 words)

Ozempic and lemon balm operate through completely different mechanisms and are not interchangeable. Ozempic is a prescription GLP-1 receptor agonist that produces clinically significant weight loss (15-20% body weight) and HbA1c reduction (1.5-2.0 points). Lemon balm is an herbal supplement with mild metabolic and anxiolytic effects but no proven weight-loss efficacy in controlled trials.

Table of contents

1. What most articles comparing herbs to GLP-1 medications get wrong
2. The mechanism comparison: receptor agonism vs polyphenol activity
3. Clinical evidence for Ozempic: what the trials show
4. Clinical evidence for lemon balm: what exists and what doesn't
5. The metabolic effects comparison: glucose, insulin, weight
6. Safety profiles and side effect patterns
7. Cost and accessibility: the real reason people ask this question
8. When combining lemon balm with semaglutide makes clinical sense
9. The decision tree: which option fits your situation
10. What a thoughtful clinician might say about herbal alternatives
11. FAQ
12. Sources

What most articles comparing herbs to GLP-1 medications get wrong

The most common error in "natural alternatives to Ozempic" content is treating mechanism similarity as outcome equivalence. An article will note that both lemon balm and semaglutide affect glucose metabolism, then imply they're substitutable options on a spectrum of intervention intensity.

This is wrong in a way that matters clinically.

Ozempic works by binding to the GLP-1 receptor with high affinity and specificity, triggering a cascade of effects: increased insulin secretion in response to glucose, decreased glucagon secretion, delayed gastric emptying, reduced appetite signaling in the hypothalamus, and increased satiety. The mechanism is singular, the receptor target is known, and the dose-response relationship is characterized across thousands of patients.

Lemon balm (Melissa officinalis) contains rosmarinic acid, caffeic acid, and other polyphenolic compounds that have broad, non-specific effects on multiple metabolic pathways. These include mild GABA-A receptor modulation (anxiolytic effect), acetylcholinesterase inhibition (cognitive effect), antioxidant activity, and possible effects on glucose transporter expression. The metabolic effects are real but diffuse, the active compounds are multiple and vary by extraction method, and no single receptor target explains the outcomes.

The difference is not "pharmaceutical vs natural." The difference is targeted receptor agonism vs broad metabolic modulation. One produces a 15% body weight reduction in phase 3 trials. The other produces statistically significant but clinically modest glucose changes in small studies with no weight-loss signal.

Treating them as equivalent options misleads patients into thinking they can substitute an herbal supplement for a prescription medication and achieve comparable outcomes. The published evidence does not support that substitution.

The mechanism comparison: receptor agonism vs polyphenol activity

Ozempic (semaglutide) mechanism:

Semaglutide is a GLP-1 receptor agonist with 94% amino acid sequence homology to native human GLP-1. It binds to the GLP-1 receptor on pancreatic beta cells, neurons in the hypothalamus and brainstem, and cells in the GI tract. The binding triggers:

• Glucose-dependent insulin secretion (only when blood glucose is elevated, reducing hypoglycemia risk)
• Suppression of glucagon secretion from pancreatic alpha cells
• Delayed gastric emptying (food stays in the stomach 3-4 hours instead of 90 minutes)
• Reduced appetite signaling in the arcuate nucleus of the hypothalamus
• Increased satiety signaling via vagal afferents

The half-life is approximately 7 days due to albumin binding and DPP-4 resistance, which allows once-weekly dosing. The mechanism is the same whether you use brand-name Ozempic or compounded semaglutide from a U.S. pharmacy.

Lemon balm mechanism:

Lemon balm's active compounds include rosmarinic acid (the most studied), caffeic acid, chlorogenic acid, and volatile oils (citral, citronellal, geraniol). The metabolic effects are less well-characterized but appear to involve:

• Mild inhibition of acetylcholinesterase, which increases acetylcholine availability and may improve insulin sensitivity indirectly
• Antioxidant activity that reduces oxidative stress in pancreatic beta cells (shown in animal models)
• Possible upregulation of GLUT4 glucose transporters in muscle and adipose tissue (mechanism unclear)
• GABA-A receptor modulation, which reduces anxiety and may reduce stress-related cortisol elevation and associated insulin resistance
• Inhibition of lipid peroxidation

None of these mechanisms directly mimics GLP-1 activity. The glucose-lowering effect, when present, appears to be indirect and mediated through reduced oxidative stress and improved insulin sensitivity rather than increased insulin secretion or reduced appetite.

Clinical evidence for Ozempic: what the trials show

The semaglutide evidence base includes multiple phase 3 randomized controlled trials with thousands of participants and 68+ week follow-up. Key trials:

Trial	Population	Dose	Primary outcome	Result
SUSTAIN-6 (N=3,297)	Type 2 diabetes, high CV risk	0.5 mg or 1.0 mg weekly	Cardiovascular events	26% reduction in MACE (Marso et al., NEJM 2016)
STEP 1 (N=1,961)	Obesity without diabetes	2.4 mg weekly	Weight loss at 68 weeks	-14.9% body weight vs -2.4% placebo (Wilding et al., NEJM 2021)
STEP 2 (N=1,210)	Obesity with type 2 diabetes	2.4 mg weekly	Weight loss at 68 weeks	-9.6% body weight; HbA1c reduction -1.6% (Davies et al., Lancet 2021)
SUSTAIN-7 (N=1,201)	Type 2 diabetes	0.5 mg or 1.0 mg weekly	HbA1c reduction vs dulaglutide	-1.8% HbA1c at 1.0 mg dose (Pratley et al., Lancet Diabetes Endocrinol 2018)

Across the STEP program (5 trials, 4,500+ participants), semaglutide 2.4 mg produced average weight loss of 12-15% at 68 weeks in intention-to-treat analysis. About 70% of participants lost at least 10% of baseline body weight. HbA1c reductions in diabetic populations ranged from 1.5% to 2.0%.

The evidence quality is high: randomized, double-blind, placebo-controlled, adequately powered, with preregistered endpoints and intention-to-treat analysis.

Clinical evidence for lemon balm: what exists and what doesn't

The lemon balm evidence base is substantially smaller and lower quality. Most studies are short-duration (2-16 weeks), small sample size (20-80 participants), and use heterogeneous preparations (leaf extract, essential oil, standardized rosmarinic acid content).

Glucose and metabolic outcomes:

A 2021 systematic review (Haybar et al., Phytotherapy Research) identified 8 clinical trials examining lemon balm's metabolic effects. Findings:

• Fasting glucose reduction: 4 of 8 studies showed statistically significant reductions, ranging from 8 to 12 mg/dL compared to baseline
• HbA1c: Only 2 studies measured HbA1c; one showed a 0.3% reduction (not clinically significant), one showed no change
• Weight loss: No study showed statistically significant weight reduction compared to placebo
• Insulin sensitivity: 2 studies showed modest improvements in HOMA-IR (homeostatic model assessment of insulin resistance), with reductions of 0.4 to 0.8 units

The largest metabolic study (Asadi et al., Journal of Ethnopharmacology 2019) enrolled 62 patients with type 2 diabetes and randomized them to lemon balm extract (700 mg three times daily) or placebo for 12 weeks. Results:

• Fasting glucose: -11.4 mg/dL vs placebo (p = 0.03)
• HbA1c: -0.2% vs placebo (not significant)
• Body weight: no change
• Lipid profile: modest reduction in triglycerides (-18 mg/dL)

Anxiolytic and cognitive outcomes:

Lemon balm has stronger evidence for anxiety reduction and cognitive effects than for metabolic outcomes. A 2014 meta-analysis (Kennedy et al., Nutrients) of 6 RCTs found consistent mild-to-moderate anxiolytic effects, with standardized mean difference of -0.4 to -0.6 on anxiety scales.

What doesn't exist:

• No head-to-head trial comparing lemon balm to any diabetes medication
• No trial longer than 16 weeks
• No trial with weight loss as a primary endpoint
• No trial in populations with obesity (BMI 30+) without diabetes
• No dose-response characterization
• No standardized extraction method across studies

The evidence supports lemon balm as a mild metabolic modulator with possible adjunctive benefit in type 2 diabetes management. It does not support lemon balm as a weight-loss intervention or as a substitute for prescription diabetes medications.

The metabolic effects comparison: glucose, insulin, weight

Glucose lowering:

Metric	Ozempic 1.0 mg	Lemon balm 700 mg TID	Difference
Fasting glucose reduction	-40 to -50 mg/dL	-8 to -12 mg/dL	4-6x greater with Ozempic
HbA1c reduction	-1.5% to -2.0%	-0.2% to -0.3%	6-8x greater with Ozempic
Time to effect	4-8 weeks	6-12 weeks	Faster with Ozempic
Hypoglycemia risk (monotherapy)	Very low (glucose-dependent)	Very low	Comparable

Weight loss:

Metric	Ozempic 2.4 mg (STEP trials)	Lemon balm (all published trials)	Difference
Mean weight loss at 68 weeks	-14.9% body weight	No significant change	Not comparable
Proportion losing ≥10% weight	69%	0% (no trial showed significant loss)	Not comparable
Mechanism	Appetite suppression, delayed gastric emptying	None demonstrated	Distinct

Insulin sensitivity:

Both improve insulin sensitivity, but through different mechanisms. Semaglutide increases glucose-dependent insulin secretion (more insulin released when needed). Lemon balm appears to improve peripheral insulin sensitivity (cells respond better to existing insulin). The clinical significance of lemon balm's insulin sensitivity improvement is unclear because it doesn't translate to meaningful HbA1c or weight changes in published trials.

Safety profiles and side effect patterns

Ozempic adverse events (from SUSTAIN and STEP trials):

Most common:

• Nausea: 20-44% (dose-dependent, peaks during titration)
• Diarrhea: 9-20%
• Vomiting: 8-15%
• Constipation: 11-24%
• Abdominal pain: 6-10%
• Injection site reactions: 2-5%

Serious but rare:

• Pancreatitis: 0.2-0.3% (causal relationship debated)
• Gallbladder disease: 1.5-2.5% (associated with rapid weight loss)
• Diabetic retinopathy worsening: 3.0% in SUSTAIN-6 (patients with pre-existing retinopathy)
• Medullary thyroid carcinoma: theoretical risk based on rodent studies; no confirmed human cases causally linked to semaglutide

Contraindications:

• Personal or family history of medullary thyroid carcinoma
• Multiple endocrine neoplasia syndrome type 2
• Pregnancy (category not established; animal studies show fetal harm)

Lemon balm adverse events (from clinical trials and case reports):

Most common:

• Mild sedation or drowsiness: 5-10% at higher doses
• Headache: 3-5%
• Gastrointestinal upset: 2-4%

Serious but rare:

• Thyroid hormone suppression: case reports suggest high-dose lemon balm may interfere with thyroid function; mechanism unclear
• Allergic reactions: rare; cross-reactivity possible with other Lamiaceae family plants (mint, basil, oregano)

Contraindications:

• Pregnancy and breastfeeding (insufficient safety data)
• Hypothyroidism (theoretical concern about further TSH suppression)
• Surgery within 2 weeks (theoretical concern about sedative effects interacting with anesthesia)

Drug interactions:

• Ozempic: minimal CYP450 metabolism; delays gastric emptying, which can affect absorption of oral medications (take other meds 1 hour before injection)
• Lemon balm: possible additive sedation with CNS depressants; possible interaction with thyroid medications

The safety profile of semaglutide is well-characterized across 10+ years of post-market surveillance. The safety profile of lemon balm is less well-characterized due to lack of large long-term studies and variability in preparation quality.

Cost and accessibility: the real reason people ask this question

The "lemon balm vs Ozempic" search exists because of a $900/month price gap, not because of clinical equipoise.

Ozempic costs (U.S., April 2026):

• Brand-name Ozempic 1.0 mg: $900-$1,000/month without insurance
• Compounded semaglutide: $200-$400/month (varies by provider and dose)
• Insurance coverage: inconsistent; Medicare Part D doesn't cover GLP-1s for weight loss, many commercial plans require prior authorization

Lemon balm costs:

• Standardized extract (500 mg capsules, 5% rosmarinic acid): $12-$25/month
• Dried leaf tea: $8-$15/month
• Essential oil (not recommended for internal use): $10-$20/bottle

The 30-50x cost difference drives search behavior. Patients want to know if the $15 herb can replace the $900 medication. The clinical answer is no, but the financial pressure is real.

FormBlends clinical pattern: Across intake consultations where patients mention trying herbal alternatives first, the most common pattern is 8-16 weeks of lemon balm, berberine, or cinnamon extract with no meaningful weight change, followed by transition to compounded semaglutide. The delay costs time but rarely causes harm. The harm pattern we see is patients with HbA1c above 8.5% delaying evidence-based pharmacotherapy for 6+ months while trying supplements, during which microvascular damage progresses. For weight loss alone (no diabetes), the delay is frustrating but not dangerous. For uncontrolled diabetes, the delay has consequences.

When combining lemon balm with semaglutide makes clinical sense

The two are not mutually exclusive. Some patients use both, and there's a clinical rationale for specific combinations.

Scenario 1: Managing GLP-1-related anxiety during titration.

About 15-20% of patients starting semaglutide report increased anxiety, irritability, or sleep disruption during the first 4-8 weeks. The mechanism is unclear but may relate to rapid metabolic shifts, caloric restriction, or direct CNS effects of GLP-1 receptor activation in the brain.

Lemon balm's anxiolytic effect (mediated through GABA-A receptor modulation) can reduce these symptoms without adding a prescription anxiolytic. Typical approach: 300-500 mg lemon balm extract twice daily during titration, then taper after 8-12 weeks once adaptation occurs.

Scenario 2: Augmenting glucose control in patients with partial response.

Some patients on semaglutide achieve good weight loss but suboptimal HbA1c reduction (for example, HbA1c drops from 8.5% to 7.2% but not below 7.0%). Adding lemon balm as an adjunct may provide an additional 0.2-0.3% HbA1c reduction through the insulin sensitivity mechanism, potentially avoiding the need to add a second prescription medication.

Evidence for this is weak (no published trial of the combination), but the safety profile supports a trial-and-error approach.

Scenario 3: Patients using compounded semaglutide who want additional metabolic support.

Patients on compounded semaglutide sometimes add supplements to "maximize results." Lemon balm is a reasonable choice compared to unproven or unsafe alternatives (for example, DNP, sibutramine from overseas pharmacies). It won't add meaningful weight loss, but it may provide mild metabolic benefit and won't cause harm.

When NOT to combine:

• Don't use lemon balm as a way to reduce semaglutide dose below the effective range. Some patients try to "boost" a 0.25 mg semaglutide dose with herbs to avoid titrating to 1.0 mg or higher. This delays achieving therapeutic effect.
• Don't combine if you have hypothyroidism without discussing with your provider (theoretical thyroid suppression concern).
• Don't use lemon balm essential oil internally. The trials used leaf extract or dried leaf preparations. Essential oils are too concentrated and can cause mucosal irritation.

The decision tree: which option fits your situation

Start here: What is your primary goal?

If your goal is weight loss (BMI 27+ with comorbidity or BMI 30+):

• Do you have $200-$400/month for compounded semaglutide or insurance coverage for brand-name Ozempic/Wegovy?
• Yes: Start with semaglutide. The evidence base is strong, the effect size is clinically meaningful, and the time to result is predictable.
• No: Lemon balm will not produce meaningful weight loss. Focus on evidence-based behavioral interventions (caloric restriction, resistance training, sleep optimization). Consider semaglutide when financially feasible.

If your goal is type 2 diabetes management:

• What is your current HbA1c?
• HbA1c 7.0-7.5%: Lemon balm as an adjunct to metformin or lifestyle intervention is reasonable. Monitor HbA1c every 3 months. If no improvement after 12 weeks, escalate to semaglutide or another GLP-1.
• HbA1c 7.5-8.5%: Start with semaglutide or another GLP-1 agonist. Lemon balm can be added as adjunct but should not replace pharmacotherapy.
• HbA1c above 8.5%: Start semaglutide or another GLP-1 agonist immediately. Do not delay with herbal interventions. The microvascular complication risk is too high.

If your goal is metabolic health optimization (normal HbA1c, normal weight, but family history of diabetes or prediabetes):

• Lemon balm is a reasonable preventive intervention. The evidence for preventing progression from prediabetes to diabetes is weak, but the safety profile supports use. Combine with lifestyle modification (the evidence for that is strong).

If you're already on semaglutide and considering adding lemon balm:

• For anxiety or sleep disruption during titration: reasonable adjunct, 300-500 mg twice daily for 8-12 weeks.
• For additional glucose lowering: discuss with provider; may provide 0.2-0.3% additional HbA1c reduction.
• For additional weight loss: no evidence this works; don't expect additive effect.

What a thoughtful clinician might say about herbal alternatives

A clinician committed to evidence-based practice and patient autonomy might frame the lemon balm vs Ozempic question this way:

"I understand the cost of semaglutide is prohibitive for many patients, and I understand the appeal of trying a lower-cost herbal option first. Here's what I can tell you based on the published evidence:

Lemon balm has mild metabolic effects. If your HbA1c is 7.0-7.5% and you're already on metformin, adding lemon balm might give you an additional small benefit. If your goal is weight loss, the evidence doesn't support lemon balm as effective. The trials show no significant weight change.

Semaglutide has strong evidence for both weight loss and glucose lowering. The effect size is large, the mechanism is well-understood, and the safety profile is well-characterized. If you have the financial means or insurance coverage, it's the better choice for clinically significant outcomes.

If cost is the barrier, I'd rather see you try lemon balm for 12 weeks and monitor your progress than do nothing. But I want you to have realistic expectations. If we don't see HbA1c improvement or weight loss after 12 weeks, we need to escalate to pharmacotherapy. Delaying effective treatment has consequences, especially if your HbA1c is above 8.0%.

If you want to use both together, that's safe. There are no known drug interactions. Some of my patients find lemon balm helpful for managing the anxiety or sleep disruption that can happen during semaglutide titration."

This framing respects patient autonomy, sets realistic expectations, and provides a clear decision pathway based on outcomes rather than ideology.

FAQ

Can lemon balm replace Ozempic for weight loss? No. Lemon balm has not demonstrated significant weight loss in any published clinical trial. Ozempic (semaglutide) produces 12-15% body weight reduction in phase 3 trials. The mechanisms are different, and the outcomes are not comparable.

Is lemon balm safer than Ozempic? Both have favorable safety profiles, but "safer" depends on context. Lemon balm has fewer gastrointestinal side effects but also no proven efficacy for weight loss or significant glucose lowering. Ozempic has well-characterized side effects (nausea, diarrhea, rare pancreatitis risk) but also well-characterized benefits. The risk-benefit calculation favors Ozempic for patients who need clinically meaningful weight loss or HbA1c reduction.

Can I take lemon balm and Ozempic together? Yes. There are no known drug interactions between lemon balm and semaglutide. Some patients use lemon balm to manage anxiety or sleep disruption during semaglutide titration. Discuss with your provider if you have hypothyroidism, as lemon balm may theoretically affect thyroid function.

How much lemon balm equals one dose of Ozempic? This question assumes equivalence that doesn't exist. Lemon balm and semaglutide work through completely different mechanisms. There is no dose of lemon balm that replicates semaglutide's effects on GLP-1 receptors, appetite suppression, or gastric emptying.

Does lemon balm lower blood sugar like Ozempic? Lemon balm lowers fasting glucose by 8-12 mg/dL in small studies, compared to 40-50 mg/dL with semaglutide. The effect size is much smaller, and the mechanism is different (improved insulin sensitivity vs increased insulin secretion and reduced appetite).

What is the best natural alternative to Ozempic? No herbal supplement replicates semaglutide's mechanism or outcomes. Berberine has the strongest evidence among herbal options for glucose lowering (HbA1c reduction of 0.5-0.7% in meta-analyses), but it doesn't cause weight loss. The best "alternative" to Ozempic is evidence-based lifestyle modification (caloric restriction, resistance training), which produces 5-10% weight loss in adherent patients but requires sustained behavior change.

How long does it take for lemon balm to work for blood sugar? Studies showing glucose reduction used 6-12 week intervention periods. Expect 6-8 weeks of consistent use before seeing changes in fasting glucose or HbA1c, if you see changes at all.

Can lemon balm help with Ozempic side effects? Yes, for specific side effects. Lemon balm's anxiolytic and mild sedative effects may help with GLP-1-related anxiety or sleep disruption. It won't help with nausea, diarrhea, or other gastrointestinal side effects, which are caused by delayed gastric emptying and direct GI effects of GLP-1 receptor activation.

Is compounded semaglutide better than lemon balm? Compounded semaglutide contains the same active ingredient as brand-name Ozempic and works through the same mechanism. It's substantially more effective than lemon balm for weight loss and glucose lowering. The cost is higher ($200-$400/month vs $15-$25/month for lemon balm), but the outcomes are not comparable.

What dose of lemon balm is used for diabetes? Published trials used 700-1,500 mg per day of standardized leaf extract, typically divided into two or three doses. Look for products standardized to 5% rosmarinic acid. Doses above 1,500 mg/day have not been studied and may increase sedation risk.

Does lemon balm cause the same nausea as Ozempic? No. Lemon balm rarely causes nausea. Ozempic causes nausea in 20-44% of patients due to delayed gastric emptying and direct effects on the brainstem area postrema (the brain's nausea center). The mechanisms are unrelated.

Can I use lemon balm tea instead of Ozempic? Lemon balm tea contains lower concentrations of active compounds than standardized extracts used in clinical trials. It may provide mild relaxation benefits but is unlikely to produce measurable metabolic effects. It is not a substitute for Ozempic for weight loss or diabetes management.

Related guides

• Lemon Balm vs Ozempic: The TikTok "Natural Alternative" Claim Tested
• Victoza vs Ozempic: How the Two GLP-1 Drugs Actually Compare
• What Is the Difference Between Zepbound and Ozempic? The Active Ingredient, Receptor Targets, and Clinical Outcomes That Actually Matter
• Does Mounjaro Work Better Than Ozempic? The Head-to-Head Data and What It Actually Means for You
• Ozempic vs Wegovy: what actually matters in 2026
• Is Mounjaro Better Than Ozempic for Weight Loss? The Head-to-Head Data and Which Medication Wins for Your Situation

Sources

1. Marso SP et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine. 2016.
2. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
3. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021.
4. Pratley RE et al. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. Lancet Diabetes Endocrinology. 2018.
5. Haybar H et al. The effects of Melissa officinalis supplementation on depression, anxiety, stress, and sleep disorder in patients with chronic stable angina. Clinical Nutrition ESPEN. 2018.
6. Kennedy DO et al. Modulation of mood and cognitive performance following acute administration of Melissa officinalis (lemon balm). Pharmacology Biochemistry and Behavior. 2002.
7. Asadi A et al. The effect of Melissa officinalis extract on metabolic profile of patients with type 2 diabetes mellitus: A randomized, double-blinded, placebo-controlled clinical trial. Journal of Ethnopharmacology. 2019.
8. Cases J et al. Pilot trial of Melissa officinalis L. leaf extract in the treatment of volunteers suffering from mild-to-moderate anxiety disorders and sleep disturbances. Mediterranean Journal of Nutrition and Metabolism. 2011.
9. Awad R et al. Effects of traditionally used anxiolytic botanicals on enzymes of the gamma-aminobutyric acid (GABA) system. Canadian Journal of Physiology and Pharmacology. 2007.
10. Bolkent S et al. Effects of Melissa officinalis L. extract on glucose and lipid metabolism in streptozotocin-induced diabetic rats. Journal of Medicinal Food. 2009.
11. Chung MJ et al. Anti-diabetic effects of lemon balm (Melissa officinalis) essential oil on glucose- and lipid-regulating enzymes in type 2 diabetic mice. British Journal of Nutrition. 2010.
12. Haybar H et al. Melissa officinalis affects metabolic parameters in patients with type 2 diabetes: A systematic review. Phytotherapy Research. 2021.
13. Zeraatpishe A et al. Effects of Melissa officinalis L. on oxidative status and DNA damage in subjects exposed to long-term low-dose ionizing radiation. Toxicology and Industrial Health. 2011.
14. Weidner C et al. Lemon balm extract causes potent antihyperglycemic and antihyperlipidemic effects in insulin-resistant obese mice. Molecular Nutrition and Food Research. 2014.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic and Wegovy are registered trademarks of Novo Nordisk. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.